Immunovia rights issue

Immunovia

Subscription price: SEK 0.06 per unit
Brokerage fee: No brokerage fee
Issuance amount: Approximately SEK 63 million
Subscription period: November 9 - November 23 2026
Trading in unit rights: November 9 - November 18 2026
Trading in BTU: Trading in BTU will take place on Nasdaq Stockholm from and including November 9 2026 until the rights issue has been registered with the Swedish Companies Registration Office
Marketplace: Nasdaq Stockholm
Company website: https://immunovia.com/

About Immunovia

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.